Y-mAbs Therapeutics (NASDAQ:YMAB) Now Covered by Oppenheimer

Oppenheimer began coverage on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a research note released on Monday morning, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $23.00 price target on the stock.

Several other research firms have also recently weighed in on YMAB. Canaccord Genuity Group reiterated a “buy” rating and issued a $26.00 target price on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 target price on shares of Y-mAbs Therapeutics in a research report on Monday, September 9th. Morgan Stanley lowered their price target on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a report on Tuesday, August 13th. Wedbush reaffirmed an “outperform” rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. Finally, BMO Capital Markets lowered their target price on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 13th. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $21.38.

Y-mAbs Therapeutics Stock Performance

Shares of YMAB stock opened at $10.10 on Monday. The stock’s 50 day simple moving average is $13.82 and its 200 day simple moving average is $12.95. Y-mAbs Therapeutics has a twelve month low of $5.29 and a twelve month high of $20.90. The company has a market capitalization of $452.38 million, a price-to-earnings ratio of -18.70 and a beta of 0.68.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The firm had revenue of $18.46 million during the quarter, compared to the consensus estimate of $23.38 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same period in the prior year, the business earned ($0.18) EPS. On average, analysts forecast that Y-mAbs Therapeutics will post -0.64 EPS for the current fiscal year.

Insider Buying and Selling at Y-mAbs Therapeutics

In other news, COO Joris Wilms sold 5,000 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $14.69, for a total transaction of $73,450.00. Following the sale, the chief operating officer now directly owns 30,600 shares of the company’s stock, valued at $449,514. This represents a 14.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Thomas Gad sold 65,000 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $13.47, for a total transaction of $875,550.00. Following the completion of the sale, the insider now directly owns 97,681 shares of the company’s stock, valued at approximately $1,315,763.07. This represents a 39.96 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 100,000 shares of company stock worth $1,338,100. 22.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Several large investors have recently made changes to their positions in the company. Ameritas Investment Partners Inc. boosted its stake in Y-mAbs Therapeutics by 39.9% in the first quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock valued at $60,000 after acquiring an additional 1,056 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Y-mAbs Therapeutics by 8.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company’s stock worth $345,000 after purchasing an additional 1,657 shares during the period. Caxton Associates LP acquired a new stake in shares of Y-mAbs Therapeutics during the first quarter worth $306,000. Boston Partners bought a new stake in Y-mAbs Therapeutics in the first quarter valued at about $556,000. Finally, Bank of New York Mellon Corp lifted its stake in Y-mAbs Therapeutics by 8.0% in the second quarter. Bank of New York Mellon Corp now owns 120,954 shares of the company’s stock valued at $1,461,000 after buying an additional 8,974 shares during the period. Institutional investors and hedge funds own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.